Angela Crook, Senior Statistician
Angela is a medical statistician with more than 25 years experience working in health research, covering a range of diseases and including roles in public health and the pharmaceutical industry. She joined the MRC CTU in 2007 and has been working in TB clinical trials since 2010.
Angela is currently the statistical lead for the programme of adult and paediatric respiratory infections trials.
Conradie F, Diacon AH, Ngubane N, Howell, P, Everitt, D, Crook AM, et al. Treatment of Highly Drug-Resistant Pulmonary Tuberculosis. The New England journal of medicine 2020; 382(10): 893-902.
Tweed CD, Dawson R, Burger DA, Conradie F, Crook AM, et al. Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial. Lancet Respir Med 2019; 7(12): 1048-58.
Crook AM, Turkova A, Musiime V, et al. Tuberculosis incidence is high in HIV-infected African children but is reduced by co-trimoxazole and time on antiretroviral therapy. BMC medicine 2016; 14: 50.
Gillespie SH, Crook AM, McHugh TD, et al. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. The New England journal of medicine 2014; 371(17): 1577-87.
Crook AM, Ford D, Gafos M, et al. Injectable and oral contraceptives and risk of HIV acquisition in women: an analysis of data from the MDP301 trial. Human reproduction 2014; 29(8): 1810-7.
TB treatment and prevention
Design and analysis of clinical trials